295 results
8-K
EX-99.1
WINT
Windtree Therapeutics Inc
17 Apr 24
Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
7:30am
for istaroxime and the Company’s other product candidates, including preclinical oncology candidates; the Company’s ability to access the debt or equity markets … in supply chain or access to potential international clinical trial sites, and through disruption, instability and volatility in the global markets, which
8-K
EX-10.1
WINT
Windtree Therapeutics Inc
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s general or specific authorization and (iv … unauthorized use, access, misappropriation or modification except in each case, where such would not, either individually or in the aggregate, reasonably
8-K
EX-2.1
6ar52hj9x9s3fa75d
8 Apr 24
Entry into a Material Definitive Agreement
4:33pm
8-K
EX-99.1
ihm 07lmpo
31 Jan 24
Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
8:00am
8-K
EX-99.1
3fx nlby2kak3cr
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
8-K
EX-1.1
he76d48yu35q
9 Nov 23
Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
4:21pm
424B5
55sb5o55v01kmccr5kkp
9 Nov 23
Prospectus supplement for primary offering
4:11pm
8-K
EX-99.1
yx2u578r4rc
7 Aug 23
Windtree Therapeutics Reports Second Quarter 2023 Financial Results and Provides Key Business Updates
4:02pm
8-K
EX-99.1
g0pe1s8
15 May 23
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
4:24pm
8-K
EX-1.1
sqf523
24 Apr 23
Entry into a Material Definitive Agreement
4:40pm
424B4
7oqsiu
20 Apr 23
Prospectus supplement with pricing info
6:03pm